Building secure obfuscation has proved brutally hard. An ideal version was proven impossible in 2001, which sent researchers after the weaker iO target instead, a roughly two-decade effort littered with broken attempts. The recent good news is that iO can now be built under reasonable security assumptions.

However, the downside is that the runtimes are, in Buterin’s word, “galactic,” efficient on paper but absurdly slow in practice.

Buterin compared the moment to where SNARKs, the zero-knowledge proofs now central to Ethereum’s scaling, sat around 2010, before years of optimization turned them from a curiosity into working infrastructure. The suggestion is that obfuscation could travel the same road from theoretical breakthrough to usable tool, even if a single run today would be hopelessly expensive.

Privacy coins like Monero (XMR) already hide things on a live blockchain, so why does Buterin treat this as unsolved? Because they hide different things. Monero obscures transaction data, such as who paid whom and how much, through ring signatures, stealth addresses and confidential amounts.

Obfuscation in Buterin’s sense hides the program’s logic, the code itself, not the data flowing through it. As he puts it, iO hides the code, not the data. Monero has done transaction privacy for over a decade, but program obfuscation has never run in production anywhere, and closing that gap is what his post is about.

The key macroeconomic factor for AUD/CAD remains the divergence in monetary policy between the two central banks. After three consecutive rate hikes since the beginning of the year, the Reserve Bank of Australia left its cash rate unchanged at 4.35%, citing persistent inflationary pressure and signs of slowing economic growth. The RBA stressed that inflation remains above its target range and that it is in no rush to begin easing policy. By contrast, the Bank of Canada has now kept its policy rate unchanged at 2.25% for a fifth consecutive meeting. Economic activity remains subdued, inflation has risen mainly due to higher energy prices, while core inflation has eased to 2.1%. The 210-basis-point interest rate differential formally supports the Australian dollar, although the RBA’s more restrictive policy cycle continues to weigh on domestic demand and limits further gains in AUD.

Technical Picture

On the four-hour chart, AUD/CAD continues to trade within a broad sideways range, bounded by green support near 0.9745 and red resistance around 0.9960. During the first half of June, a local bullish trend developed within the range; however, in the latter part of the month, the price broke below the trendline and fell beneath the lower boundary of the current market profile at 0.9838. The POC zone is concentrated between 0.9917 and 0.9920 and could act as resistance should the market reverse higher.

Given the close proximity of the POC zone, the upper boundary of the profile at 0.9942, and the resistance level itself, this cluster may attract increased selling interest. Current horizontal volume remains moderate, suggesting the absence of a clear market bias. RSI + MAs shows readings of 34, 33, 38. The RSI has already entered oversold territory, while the moving averages, although coloured red, remain broadly horizontal.

Key Takeaways

The pair continues to trade within its established range, lacking a catalyst for a decisive breakout. The RSI has moved out of oversold territory, while the moving averages, although still red, have lost their directional bias. Further price action will largely depend on how the market reassesses expectations for the RBA’s policy path amid signs of slowing growth in the Australian economy.

Trade over 50 forex markets 24 hours a day with FXOpen. Take advantage of low commissions, deep liquidity, and spreads from 0.0 pips (additional fees may apply). Open your FXOpen account now or learn more about trading forex with FXOpen.

This article represents the opinion of the Companies operating under the FXOpen brand only. It is not to be construed as an offer, solicitation, or recommendation with respect to products and services provided by the Companies operating under the FXOpen brand, nor is it to be considered financial advice.

Key Takeaways

• Zymeworks has entered into an agreement to purchase Theravance Biopharma in an all-cash transaction valued at $929 million at $17 per share
• Acquisition pricing represents a 3.6% decrease compared to Theravance’s previous closing price of $17.63
• Yupelri, Theravance’s sole commercialized product for COPD treatment approved by FDA, recorded $266.6 million in 2025 U.S. net revenue
• Premarket trading showed Theravance shares declining 2.8% while Zymeworks decreased 1.4%
• Transaction completion is anticipated during the latter half of 2026 and projected to boost Zymeworks’ earnings and cash generation

In a significant consolidation move, Zymeworks has reached a definitive agreement to purchase Theravance Biopharma through an all-cash transaction totaling $929 million, offering shareholders $17 per share — representing a 3.6% reduction from Theravance’s Friday closing value of $17.63.

Zymeworks Inc., ZYME

Investor sentiment reflected skepticism. During Monday’s premarket session, Theravance shares declined 2.8% to $17.14. Zymeworks experienced a 1.4% pullback.

The below-market pricing is atypical in merger and acquisition activity and clarifies the negative market reaction. Most buyout transactions include a premium above current trading levels.

Neverthstanding, the transaction does provide a 22% markup relative to Theravance’s March 3 valuation, immediately following the announcement of late-stage clinical trial disappointment for ampreloxetine — a therapy candidate targeting a rare medical condition.

The unsuccessful trial prompted Theravance to initiate a corporate reorganization, resulting in workforce reductions of approximately 50%. Subsequently, management commenced a strategic review process, including potential sale scenarios.

Monday’s announcement effectively concludes that strategic evaluation period.

Assets Acquired by Zymeworks

The centerpiece of this transaction is Yupelri, a nebulized once-daily medication for chronic obstructive pulmonary disease already available commercially. This represents Theravance’s only marketed pharmaceutical product.

Yupelri achieved $266.6 million in U.S. net revenue during 2025, reflecting 12% growth versus the prior year. First quarter 2026 U.S. net revenue reached $62.4 million, demonstrating 7% year-over-year expansion.

Theravance maintains a 35% net profit participation arrangement for Yupelri within the United States, where commercialization occurs through a partnership with Viatris. According to Zymeworks, these royalty streams and profit-sharing arrangements currently deliver approximately $60 million in annualized cash generation.

This acquisition represents a strategic pivot for Zymeworks — historically concentrated in oncology therapeutics — establishing presence in the respiratory disease sector alongside major pharmaceutical companies like GSK, AstraZeneca, and Boehringer Ingelheim.

Future of Ampreloxetine Program

The unsuccessful development candidate remains part of the transaction structure. Under deal terms, Theravance shareholders will obtain contingent value rights entitling them to 80% of net proceeds resulting from future licensing arrangements, asset sales, or alternative monetization transactions involving ampreloxetine during the next decade.

Zymeworks retains the remaining 20% interest and has indicated intentions to explore monetization opportunities for this asset.

Zymeworks management projects the acquisition will enhance earnings and cash flow generation following transaction completion, targeted for the second half of 2026.

Completion remains contingent upon regulatory clearance and approval from Theravance shareholders.

Yupelri’s first quarter 2026 U.S. net revenue performance of $62.4 million marked 7% advancement compared to the corresponding period in the previous year.

Strategy (MSTR) unveiled a new Digital Credit Capital Framework on Monday, introducing a series of capital management initiatives designed to strengthen its preferred securities, preserve long term bitcoin exposure, and improve balance sheet flexibility.

The company has already adopted a board approved U.S. dollar reserve policy and increased the annual dividend rate on its Variable Rate Series A Perpetual Stretch Preferred Stock (STRC) to 12%, effective for dividend periods beginning July 1. Strategy said its U.S. dollar reserve currently stands at approximately $2.55 billion, enough to cover about 17.4 months of preferred dividend and interest obligations.

The board also authorized, but did not commit to, up to $1 billion in repurchases of its Digital Credit Securities and up to $1 billion in buybacks of its Class A common stock. The programs have no fixed expiration date and may be modified, suspended, or terminated at any time. Actual repurchases will depend on market conditions and management’s assessment that they are accretive.

IRACE is not alone in betting that institutions want fewer providers and more integrated infrastructure. In April, SoFi unveiled Big Business Banking, a platform that lets companies manage fiat banking and crypto-related operations through a single regulated bank. The service signed up major digital asset firms including CoinDesk’s parent company Bullish (BLSH), BitGo (BTGO), Cumberland and Wintermute, highlighting a broader industry move toward combining traditional banking, payments and digital asset services under one roof.

As part of the rebrand, IRACE appointed former Zodia Custody CEO John Cronin as global CEO. Several other former Zodia executives, including Jo Lee, Niamh Byrne and Jennifer Fisher, have also joined the company in senior leadership roles.

“Institutional clients today are forced to stitch together banking, custody, payments, liquidity and execution across multiple providers, each with its own controls, reporting and operational risk,” Cronin said in the release.

“IRACE is being built to unify that stack into a single institutional platform — one operating model, one governance framework, one set of controls — supporting fiat, stablecoins, and both traditional and digital assets. That is what institutional scale across these markets actually requires,” he added.

IRACE operates regulated banking businesses across the U.S., Europe and the Cayman Islands. The company said it is pursuing additional regulatory approvals related to digital asset services in multiple jurisdictions.

The crypto market outlook remains fragile. Rising concerns about Federal Reserve interest-rate increases, a strengthening dollar, higher U.S. Treasury yields, record ETF outflows and airstrikes in the Middle East offer bitcoin BTC$59,717.65 bulls little reason for optimism.

Yet the market dynamics carry a glimmer of hope.

Bullish positioning, especially in the Dollar Index and interest-rate markets, is beginning to look lopsided. That’s the kind of crowded setup that often unwinds with a snap adjustment and a contrarian, counter-trend move. Should that occur, it would probably take the form of a sudden drop in the dollar and yields, which could put a strong floor under bitcon’s price.

The crowding shows up clearly in the data. Figures from the CFTC and ICE Europe show the aggregate net long dollar position rose 18% to $34.5 billion in the week ended June 22, the highest in seven years. That’s a sharp reversal from the net short position before the Iran conflict began in February.

Rates markets tell a similar story. Leveraged funds’ short bets in Secured Overnight Financing Rate (SOFR) futures hit a record 2.97 million contracts. That constitutes over $700 billion in notional bets on rising interest rates, according to Saxo Bank.

Everyone is watching the CLARITY Act for what it does to crypto market structure. Buried inside it is a provision with a different target entirely: a ban on a US central bank digital currency. It is literally one of the bill’s three names. Here is what the anti-CBDC provision does, why it is there, and why it may matter more for stablecoins than for anything else.

Almost everyone watching the CLARITY Act is watching it for one reason: it would settle the long fight over whether crypto tokens are securities or commodities, reshaping how the entire digital-asset market is regulated. That is the headline, and it is a big one. But folded inside the same bill is a provision aimed at something completely different, a ban on a United States central bank digital currency, and it is not a minor footnote. 

The anti-CBDC language is so integral to the legislation that it is one of the bill’s three official short titles: the same act is named the Digital Asset Market Clarity Act, the CLARITY Act, and the Anti-CBDC Surveillance State Act. In other words, stopping a government digital dollar is not a rider quietly attached to the bill; it is one of the bill’s stated purposes, written into its very name. Yet because the market-structure debate consumes nearly all the attention, the CBDC ban has traveled largely under the radar, which is exactly why it is worth examining on its own.

The reason this matters extends well beyond a technical change to the Federal Reserve Act. A ban on a US central bank digital currency touches some of the most charged questions in money today: financial privacy, government surveillance, the future of the dollar, and, most concretely for crypto, the competitive fate of private stablecoins. Removing the possibility of a government-issued digital dollar does not just settle a privacy debate; it clears the field of the one competitor that could have challenged the private stablecoins now becoming central to crypto and payments. 

This piece explains what the anti-CBDC provision actually does, what a central bank digital currency is and why it generates such fierce opposition, the political case behind the ban, the bigger prize of a protected lane for private stablecoins, the several parallel tracks on which the ban is moving, the serious arguments against it, and what it all means for crypto holders. The market-structure fight may decide how crypto is regulated, but the CBDC provision could quietly shape who wins the payments future, which makes it one of the most consequential parts of the bill almost nobody is discussing.

What the provision actually does

Start with the mechanics, because the provision is specific. The anti-CBDC language amends the Federal Reserve Act to impose several related prohibitions on the central bank. It bars the Federal Reserve banks from offering certain products or services directly to individuals, which is the structural feature a retail digital dollar would require, since a true retail CBDC would mean ordinary people holding accounts or balances directly with the Fed. 

It prohibits the Fed from issuing a central bank digital currency, or any digital asset substantially similar to one, directly to individuals or indirectly through financial institutions or other intermediaries. It prohibits the use of a central bank digital currency to conduct monetary policy. And in its fuller forms, the anti-CBDC framework also bars the Fed from even testing or developing a CBDC without explicit authorization from Congress.